SANARE spol s. r.o, Work Place: Private Dermatological Clinic, DOST, Svidník, Slovakia.
La Roche-Posay International, Levallois-Perret, France.
J Eur Acad Dermatol Venereol. 2023 Jun;37 Suppl 5:27-34. doi: 10.1111/jdv.18947. Epub 2023 Apr 24.
Emollients are the baseline treatment for mild or moderate atopic dermatitis (AD) to improve the epidermal barrier and provide anti-irritant and anti-pruritic effects. Emollient 'plus' can influence the skin microbiome of atopic eczema patients.
To evaluate the benefits of using Emollient 'plus' to reduce corticosteroid consumption.
In an open, single-centre, randomized, controlled study, patients with mild to moderate AD (Severity scoring of AD [SCORAD] score 20-30) were randomized 1:1 to apply the Emollient 'plus' twice daily for 28 days or to continue with their usual classical emollient (Control group). In addition, each patient received topical corticosteroids to use when necessary and according to the dermatologist's prescription. Assessments included SCORAD, PO-SCORAD, local SCORAD, quality of life questionnaires, and tolerability.
A total of 119 patients were included in the PP population with a mean age of 26.50 ± 17.5 years old (min-max 3-71 years). Between baseline and day 28, the mean amount of corticosteroid used was lower for the Emollient 'plus' versus Control group (6.03 vs. 9.16 g; p = 0.041) and corticosteroid was applied on fewer days (37.5% vs. 46.9% of days; p = 0.0256) with fewer applications per day (0.55 vs. 0.71 applications per day; p = 0.0203). Similar improvements were observed in both groups for SCORAD, PO-SCORAD, local SCORAD, skin sensation score, AD burden scale, patient benefit index >1, as well as subject and investigator efficacy and tolerability questionnaire assessments.
Between baseline and day 28, there was significant corticosteroid-sparing in the Emollient 'plus' group compared to the Control group in quantity, number of applications per day and number of days of use, whilst efficacy was maintained with no significant differences between the two groups for all clinical evaluations, as well as for tolerability.
润肤剂是治疗轻度或中度特应性皮炎（AD）的基础疗法，可改善表皮屏障并提供抗刺激和止痒作用。润肤剂“加”可以影响特应性皮炎患者的皮肤微生物组。
评估使用润肤剂“加”来减少皮质类固醇消耗的益处。
在一项开放、单中心、随机、对照研究中，将轻度至中度 AD（AD 严重程度评分[SCORAD]评分 20-30）患者随机分为 1:1 组，每天使用两次润肤剂“加”，持续 28 天，或继续使用其常规经典润肤剂（对照组）。此外，每位患者在必要时根据皮肤科医生的处方使用局部皮质类固醇。评估包括 SCORAD、PO-SCORAD、局部 SCORAD、生活质量问卷和耐受性。
共有 119 名患者纳入 PP 人群，平均年龄为 26.50±17.5 岁（最小-最大 3-71 岁）。与基线相比，在第 28 天，与对照组相比，润肤剂“加”组的皮质类固醇使用量较低（6.03 克 vs. 9.16 克；p=0.041），且皮质类固醇使用天数更少（37.5% vs. 46.9%的天数；p=0.0256），每天的应用次数也更少（0.55 次 vs. 0.71 次/天；p=0.0203）。两组的 SCORAD、PO-SCORAD、局部 SCORAD、皮肤感觉评分、AD 负担量表、患者获益指数>1 以及患者和研究者疗效和耐受性问卷评估均观察到类似的改善。
与基线相比，在第 28 天，与对照组相比，润肤剂“加”组的皮质类固醇用量、每日应用次数和使用天数均显著减少，而两组在所有临床评估以及耐受性方面均无显著差异。
